- 0 items in basket
- Total £0
- $0 / €0
- View Basket
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharma Chemicals
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
- Market Reports
Customer Services
All Change in the US Pharma Market?
| Product Code | ESP00512 |
|---|---|
| Publication Date | June 2008 |
| Publisher | Espicom |
| Product Type | Report |
| Pages | 186 |
| ISBN Number | 978-1-85822-321-6 |
Buy this product or for assistance call +44 20 7060 7474
This extensive report provides a unique analysis of the likely impact of generic competition in the US pharma market. Now you can...
- Identify the 150 products which could be subject to generic competition over the next 5 years
- Evaluate the level of impact on each product
- Assess the impact of generic competition on 14 leading branded companies
- Understand the strategies being used by companies in defence of their products' position
Key questions answered in this report
- Which companies are at greater or lesser risk of generic competition by 2012 and what will be the impact on revenues?
- What strategies has Abbott successfully employed in defence of Depakote and Tricor?
- Who is benefiting from the unresolved biosimilar approval process?
- AstraZeneca could have US$5.31 billion of revenue at risk by 2012 - what are the products affected and when will the impact be felt?
- What lessons can be learned from the ongoing Apotex/BMS and SA litigation in relation to the world's second best selling drug Plavix?
- There is much discussion about generic competition to Lipitor, but what other products are at risk in Pfizer's portfolio?
- Why has Wyeth not sued Sun Pharmaceutical over its extended release tablet for Effexor?
Understand the developments that are driving change
- All Change in the US Pharma Market?
- The rise of generics, products at risk and defence strategies
- Foreword
- Executive Summary
- Industry Overview
- Branded company sales overview
- Leading Originator Companies, Global Pharmaceutical Revenues, 2006-07 (US$ millions)
- Exposure to generics of Global Revenues Likely to Face Generic Competition, 2008-12
- Branded defence strategies
- Incremental innovation
- Extended-release formulations
- Second-generation products
- Citizen petitions
- Deals with generic companies
- Authorised generics
- Biologics
- Leading Originator Companies, PHSA Biologic Revenues 2007
- FDCA biologics
- Generic Approvals and Launches
- Pharmaceutical Products Estimated to Face Widespread Generic Competition by 2012
- Pharmaceutical Products Estimated to Face Limited Generic Competition by 2012
- Pharmaceutical Products Estimated to Face No Generic Competition by 2012
- Biologic Products: No Generic Competition to 2012
- 2007 Global Revenues Subject to Generic Competition by 2012 (US$ millions)
- Generic launches at risk?
- Summary of at risk? US Generic Launches, 2006-08
- Research-Based Company Profile
- Abbott Laboratories
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Biaxin
- Depakote/Depakote ER
- Humira
- Kaletra
- Omnicef
- Synthroid
- Tricor
- A mgen
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- US Product Sales Data, 2006-07 (US$ millions)
- Aranesp
- Epogen
- Neulasta
- Neupogen
- Enbrel
- Sensipar
- Vectibix
- AstraZeneca
- Sales Intro
- Exposure to generics 2008-12
- Defence Strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- US Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
- 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Arimidex
- Atacand
- Casodex
- Crestor
- Nexium
- Prilosec
- Pulmicort
- Seroquel
- Toprol XL
- Zoladex
- Zomig
- Boehringer Ingelheim
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (euros millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (euro millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Aggrenox
- Combivent
- Flomax
- Micardis
- Mirapex
- Mobic
- Spiriva
- Bristol-Myers Squibb
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- US Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 ( billions)
- 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Abilify
- Avapro/Avalide
- Baraclude
- Erbitux
- Orencia
- Plavix
- Pravachol
- Reyataz
- Sprycel
- Sustiva
- Eli Lilly
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- US Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
- 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Alimta
- Byetta
- Cialis
- Cymbalta
- Evista
- Forteo
- Gemzar
- Humatrope
- Strattera
- Zyprexa
- Insulin products
- GlaxoSmithKline
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 ( millions)
- US Product Sales Data, 2006-07 ( millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 ( billions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 ( billions)
- 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Advair Diskus
- Augmentin
- Avandia
- Avodart
- Combivir
- Coreg
- Epzicom
- Flonase
- Flovent
- Imitrex
- Lamictal
- Paxil
- Requip
- Trizivir
- Valtrex
- Wellbutrin
- Zofran
- Johnson & Johnson
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Aciphex
- Concerta
- Duragesic
- Levaquin
- Procrit
- Remicade
- Risperdal
- Topamax
- Merck & Co
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Cancidas
- Cozaar
- Emend
- Fosamax
- Januvia
- Maxalt
- Primaxin
- Proscar/Propecia
- Singulair
- Trusopt/Cosopt
- Zocor
- Novartis
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- US Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Diovan
- Exelon
- Famvir
- Femara
- Focalin
- Gleevec
- Lamisil
- Lescol XL
- Lotrel
- Sandostatin
- Trileptal
- Zometa
- Pfizer
- Sales Intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- 2007 Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
- 2007 Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Aricept
- Aromasin
- Caduet
- Camptosar
- Cardura
- Celebrex
- Chantix
- Detrol/Detrol LA
- Genotropin
- Geodon Oral
- Lipitor
- Lyrica
- Neurontin
- Norvasc
- Relpax
- Sutent
- Vfend
- Viagra/Revatio
- Xalatan
- Zithromax
- Zoloft
- Zyrtec
- Zyvox
- Roche
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (CHF millions)
- US Product Sales Data, 2006-07 (CHF millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (CHF millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (CHF millions)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Avastin
- Boniva
- CellCept
- Herceptin
- Kytril
- Lucentis
- Nutropin
- Pegasys
- Rituxan
- Tamiflu
- Tarceva
- Valcyte
- Xeloda
- Xenical
- Xolair
- Sanofi Aventis
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (euro millions)
- US Product Sales Data, 2006-07 (euro millions)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (euros millions)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Actonel
- Allegra
- Amaryl
- Ambien
- Avapro
- Copaxone
- Deprocon
- Eloxatine
- Lantus
- Lovenox
- Nasacort
- Plavix
- Taxotere
- Altace
- Uroxatral
- Wyeth
- Sales intro
- Exposure to generics 2008-12
- Defence strategies
- Product Summary, 2006-2012
- Summary of Products Reviewed
- Summary by Year
- Global Product Sales Data, 2006-07 (US$ millions)
- US Product Sales Data, 2006-07 (US$ millions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (US$ billions)
- 2007 Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- 2007 US Revenues Exposed To Probable Generic Competition, 2008-12 ( billions)
- 2007 US Global Revenues Exposed To Probable Generic Competition, 2008-12 (% of Total)
- Effexor
- Prevnar
- Protonix
- Zosyn/Tazocin
- Tygacil
- Appendix: Overview of the generic application and approval system
- Appendix 1: ANDA Approvals
- ANDA Approvals, 2002-08
Delivery Details
PDF:Delivered by email usually within 4 to 8 UK business hours.
© 2010| Report Buyer is a trading name for Piribo Ltd. Registered in England and Wales No. 05051530 | VAT Reg No. GB 839 4556 85
